Melissa R Junttila

List of Publications by Year
in descending order

20 papers	2,137 citations	17 h-index 471509	21 g-index 713466
22 all docs	22 docs citations	22 times ranked	4801 citing authors

#	Article	IF	Citations
1	Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discovery, 2020, 10, 232-253.	9.4	466
2	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 4284-4292.	1.6	431
3	Translational value of mouse models in oncology drug development. Nature Medicine, 2015, 21, 431-439.	30.7	242
4	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. Npj Precision Oncology, 2018, 2, 7.	5.4	107
5	A Stromal Niche Defined by Expression of the Transcription Factor WT1 Mediates Programming and Homeostasis of Cavity-Resident Macrophages. Immunity, 2019, 51, 119-130.e5.	14.3	105
6	Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6079-6084.	7.1	101
7	RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death and Differentiation, 2020, 27, 161-175.	11.2	100
8	Transcription factor Etv5 is essential for the maintenance of alveolar type II cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3903-3908.	7.1	94
9	Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment. Clinical Cancer Research, 2018, 24, 4455-4467.	7.0	88
10	Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PLoS ONE, 2017, 12, e0185862.	2.5	67
11	<i>Kras</i> mutant genetically engineered mouse models of human cancers are genomically heterogeneous. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10947-E10955.	7.1	58
12	Lymph node-independent liver metastasis in a model of metastatic colorectal cancer. Nature Communications, 2014, 5, 3530.	12.8	57
13	Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer. Molecular Cancer Therapeutics, 2015, 14, 40-47.	4.1	48
14	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	46.4	41
15	Castration-Resistant Lgr5+ Cells Are Long-Lived Stem Cells Required for Prostatic Regeneration. Stem Cell Reports, 2015, 4, 768-779.	4.8	36
16	Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation. Cell Death and Differentiation, 2019, 26, 2416-2429.	11.2	25
17	Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells. Nature Communications, 2018, 9, 2992.	12.8	23
18	CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Reports, 2022, 38, 110351.	6.4	18

#	Article	IF	Citations
19	Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis. Translational Oncology, 2015, 8, 126-135.	3.7	14
20	Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1162-1173.	7.0	13